Lupin Gets Nod From USFDA To Market Anti Fungal Capsules

न्यूज़ वर्ल्ड इंडिया | 0
| July 10 , 2017 , 16:41 IST

The US health regulator has given Drug firm Lupin the green light to use Flucytosine capsules which can be used for the treatment of the fungal infections.

The USFDA which stands for the United States Food and Drug Administration has given drug maker Lupin the final approval so that they can market the medicine which will be in 250mg and 500mg.

This medicine will be similar to the Ancobon capsules which are produced by Valeant Pharmaceuticals International Inc.

Also Read: Vijay Mallya Fails To Show Up In Court Despite Supreme Court Orders

The capsules are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus, Lupin said.

As per IMS MAT March 2017 data, Ancobon capsules had US sales of $46.6 million, it added.

Shares of Lupin Ltd were on Monday trading at Rs1,152.75 per scrip in the afternoon trade on BSE, up 3.22% from its previous close.

(inputs from pti)


Thank you so much for this track. So now come here and get the benefit for the make a best fix windows 10 mobile connections connection of the system and come here.